Akston has used its Ambifect™ Fc-fusion protein platform to develop a diverse pipeline of therapeutic candidates for indications in both human and animal health.
Akston has licensing agreements with partners and maintains close involvement in the development process.
Human Health
AKS-452 is a CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. Akston and Strides Group have signed a licensing, manufacturing, and commercialization agreement to launch AKS-452 worldwide as AmbiVax-C™.
Akston has developed AKS-107, a designer Fc-insulin fusion protein, to interrupt the process leading to insulin autoimmunity. Akston has partnered with the Helmsley Charitable Trust and the National Institutes of Health (NIH).
once-a-week dosing
Akston has developed AKS-440, a novel human insulin candidate based on the Ambifect™ Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. It is currently in pre-clinical development.
Akston has developed AKS-130, an insulin-Fc fusion protein designed to lower blood glucose levels in order to target the tumor cell insulin receptors. It is currently in pre-clinical development.
Animal Health
once-a-week dosing
Akston has developed AKS-321d, a once-a-week insulin therapies for dogs intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-321d.
once-a-week dosing
Akston has developed AKS-425c, a once-a-week insulin therapies for cats intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-425c.
